External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

Teladoc Health, Inc. provides healthcare services. The Company diagnoses, recommends treatment, and prescribes medication for routine medical issues through phone and video consultations. Teladoc operates in the United States.

<ul><li>Teladoc is the largest telehealth provider in the US with over 92 million members in its B2B network and 400,000 paying users for BetterHelp</li><li>The company has experienced a decline in stock value due to expensive acquisitions, growth challenges, and leadership changes</li><li>Despite setbacks, Teladoc's scale, profitability, and potential to offer comprehensive solutions may position it as a survivor in the competitive telehealth industry.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Teladoc is the largest telehealth provider in the US with over 92 million members in its B2B network and 400,000 paying users for BetterHelpThe company has experienced a decline in stock value due to expensive acquisitions, growth challenges, and leadership changesDespite setbacks, Teladoc's scale, profitability, and potential to offer comprehensive solutions may position it as a survivor in the competitive telehealth industry.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Teladoc Health Inc (TDOC) - Friday, Aug 23, 2024

Indian Accounting Research Analyst, Trudence Capital Advisors

Nitin Mangal

Indian Accounting Research Analyst

Trudence Capital Advisors

Trudence Capital Advisors Private Limited is a SEBI-registered Research Analyst, holding SEBI registration number INH000015747. Our firm is dedicated to providing independent and unbiased research on Indian mid to large-cap companies. Trudence Capital is known for its counter-consensus views, with a focus on forensic research and on-ground primary investigations. Our research approach is thorough, involving detailed analysis of accounting practices and governance, alongside extensive channel checks.

Independent & Unbiased Research

Forensic Accounting

Narayana Hrudayalaya Ltd / Forensic Accounting

Narayana Hrudayalaya Limited operates a network of hospitals. The Company offers cardiac surgery, cardiology, diabetes and endocrinology, gastroenterology, general surgery, neuroscience, facial surgery, nephrology, obstetrics and gynecology, orthopedics, oncology, pediatrics, transplant, and urology services. Narayana Hrudayalaya serves patients worldwide.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/narayana-hrudayalaya-ltd" target="_blank" data-smartkarma-citation="entities:26939:1" rel="noopener">Narayana Hrudayalaya Ltd (NARH IN)</a> is on an expansion spree and looks to add further 1500 beds in the next four years, to its 5683 operational beds as at FY24.</li>
<li>As far as forensics are concerned, the company has shown improvement in its capital allocation, shown ramp up/turnaround in some hospitals; also impairments are done with in the past. </li>
<li>However, few concerns loom over PPE disposals and non-reconciliation with cash flows, treatment of reversal of provisions and high growth rate assumed in goodwill CGU.</li>
</ul>



Narayana Hrudayalaya Ltd (NARH IN) is on an expansion spree and looks to add further 1500 beds in the next four years, to its 5683 operational beds as at FY24.
As far as forensics are concerned, the company has shown improvement in its capital allocation, shown ramp up/turnaround in some hospitals; also impairments are done with in the past. 
However, few concerns loom over PPE disposals and non-reconciliation with cash flows, treatment of reversal of provisions and high growth rate assumed in goodwill CGU.


Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Bristol Myers Squibb Co / Equity Bottom-Up

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant  rejection, and psychiatric disorders.

<ul><li>Bristol-Myers Squibb's third quarter 2024 earnings highlight a period of robust growth and strategic advancements, albeit accompanied by challenges typical of large pharmaceutical companies.</li><li>On the positive side, the company reported a noteworthy 20% revenue increase in its growth portfolio at constant currency, which now contributes to approximately half of the total revenues.</li><li>This growth is supported by products with exclusivity extending into the next decade, underscoring the company’s successful pipeline development and launch of new therapies.</li></ul>

Bristol-Myers Squibb's third quarter 2024 earnings highlight a period of robust growth and strategic advancements, albeit accompanied by challenges typical of large pharmaceutical companies.On the positive side, the company reported a noteworthy 20% revenue increase in its growth portfolio at constant currency, which now contributes to approximately half of the total revenues.This growth is supported by products with exclusivity extending into the next decade, underscoring the company’s successful pipeline development and launch of new therapies.

Bristol-Myers Squibb: Expansion into Alzheimer's Disease Psychosis Treatment As A Key Growth Catalyst! - Major Drivers

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.

<ul><li>AbbVie has reported noteworthy third-quarter results for 2024, outperforming expectations with strong core growth driven largely by its ex-HUMIRA platform.</li><li>The company's diversified portfolio highlighted significant achievements, with sales reaching $260 million above forecasts and demonstrating robust mid-single-digit operational sales growth.</li><li>The impressive performance of SKYRIZI and RINVOQ has been particularly pivotal, contributing to a projected combined sales of over $17 billion for the year, surpassing initial expectations by $1.3 billion.</li></ul>

AbbVie has reported noteworthy third-quarter results for 2024, outperforming expectations with strong core growth driven largely by its ex-HUMIRA platform.The company's diversified portfolio highlighted significant achievements, with sales reaching $260 million above forecasts and demonstrating robust mid-single-digit operational sales growth.The impressive performance of SKYRIZI and RINVOQ has been particularly pivotal, contributing to a projected combined sales of over $17 billion for the year, surpassing initial expectations by $1.3 billion.

AbbVie Inc.: The SKYRIZI & RINVOQ Revolution: Capturing Market Share with Game-Changing Therapies! - Major Drivers

Merck & Co., Inc.  is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.

<ul><li>Merck & Co. has demonstrated robust operational performance and strategic advances in its third quarter earnings, navigating through both burgeoning opportunities and prevailing challenges.</li><li>The company's financials exhibited a 4% revenue growth, or 7% on a constant currency basis, driven by enhanced global uptake of KEYTRUDA in oncology, favorable launches of products like WINREVAIR and CAPVAXIVE, and a strong performance in the Animal Health sector.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Merck & Co. has demonstrated robust operational performance and strategic advances in its third quarter earnings, navigating through both burgeoning opportunities and prevailing challenges.The company's financials exhibited a 4% revenue growth, or 7% on a constant currency basis, driven by enhanced global uptake of KEYTRUDA in oncology, favorable launches of products like WINREVAIR and CAPVAXIVE, and a strong performance in the Animal Health sector.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Merck & Co. Inc.: Expanding Oncology Portfolio through KEYTRUDA Developments & Partnership Collaborations To Shape the Future! - Major Drivers